ClinicalTrials.gg
CompletedNCT05051579Updated Sep 13, 2023Results posted

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

A Phase 2 interventional study of LY3502970 and Placebo in Obesity and Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 35 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.

Enrollment
12th of 22
272 · median 324
Started
2021
the only one that year
Phase 2
Only one
of the 22
Registered
1st of 22
by date
Lead sponsor
21 of 22
Eli Lilly and Company

Among the 22 studies testing orforglipron in Obesity, this one is the 12th largest by enrollment, is the only one that started in 2021, is the only one in phase 2, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing orforglipron in Obesity, or all of them as a file.
02

Study summary

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

03

Conditions studied

  • Obesity
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of ≥30-kilogram square meter (kg/m²)
  • Have a BMI ≥27 kg/m² and \<30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
  • Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

Exclusion criteria

Exclusion Criteria:

  • Have any prior diagnosis of diabetes
  • Have a prior or planned surgical treatment for obesity
  • Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
  • Have renal impairment measured as estimated (eGFR) \<30 milliliter (mL)/minute (min)/1.73 m²
  • Have a history of acute chronic pancreatitis
  • Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

  • Have poorly controlled hypertension
  • Have history of acute myocardial infarction
  • Have history of cerebrovascular accident (stroke)
  • Had hospitalization due to congestive heart failure (CHF)
  • Have cancer
  • Have (HIV) and/or positive HIV antibodies historically or at screening
  • Have and/or positive hepatitis B surface antigen
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    12 milligram (mg) LY3502970

    Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.

    Drug: LY3502970

  • Experimental
    24 mg LY3502970

    Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.

    Drug: LY3502970

  • Experimental
    36 mg-1 LY3502970

    Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

    Drug: LY3502970

  • Experimental
    36 mg-2 LY3502970

    Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.

    Drug: LY3502970

  • Experimental
    45 mg-1 LY3502970

    Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

    Drug: LY3502970

  • Experimental
    45 mg-2 LY3502970

    Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.

    Drug: LY3502970

  • Placebo comparator
    Placebo

    Participants received placebo administered orally once daily until 36 weeks.

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight in LY3502970 and Placebo

    Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Percent Change From Baseline in Body Weight in LY3502970 and Placebo

    LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 36

  2. Change From Baseline in Body Weight in LY3502970 and Placebo

    LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 26

  3. Change From Baseline in Body Weight in LY3502970 and Placebo

    LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 36

  4. Change From Baseline in Waist Circumference in LY3502970 and Placebo

    LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 26

  5. Change From Baseline in Waist Circumference in LY3502970 and Placebo

    LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 36

  6. Change From Baseline in BMI in LY3502970 and Placebo

    LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 26

  7. Change From Baseline in BMI in LY3502970 and Placebo

    LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 36

  8. Percentage of Participants With >=5% Body Weight Loss

    Percentage of participants with \>=5% body weight loss was reported.

    Time frame: Week 26

  9. Percentage of Participants With >=10% Body Weight Loss

    Percentage of participants with \>=10% body weight loss was reported.

    Time frame: Week 26

  10. Percentage of Participants With >=5% Body Weight Loss

    Percentage of participants with \>=5% body weight loss was reported.

    Time frame: Week 36

  11. Percentage of Participants With >=10% Body Weight Loss

    Percentage of participants with \>=10% body weight loss was reported.

    Time frame: Week 36

07

Results

Posted Sep 13, 2023

Participant flow

Participant flow — Overall Study
Milestone12 mg LY350297024 mg LY350297036 mg -1 LY350297036 mg -2 LY350297045 mg -1 LY350297045 mg -2 LY3502970Placebo
Started50532929313050
Completed44462724232843
Not completed6725827
Withdrew: Withdrawal by subject3521404
Withdrew: Lost to follow-up1000101
Withdrew: Subject unable to visit due to working out of town0000001
Withdrew: Adverse event2104120
Withdrew: Inadvertent enrollment0000001
Withdrew: Subject could not tolerate investigational product (ip) and was taken off0100000
Withdrew: Sponsor decision0000100
Withdrew: Patient was initially long term follow-up but contacted and came to site after follow-up0000100

Outcome measures

PrimaryPercent Change From Baseline in Body Weight in LY3502970 and Placebo

Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight in LY3502970 and Placebo
Percent change12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Percent Change From Baseline in Body Weight in LY3502970 and Placebo-8.6 ± 0.85-11.2 ± 0.82-12.3 ± 0.77-12.6 ± 0.75-2.0 ± 0.81
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -6.5 · 95% CI -8.9 to -4.2
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -9.2 · 95% CI -11.5 to -6.9
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.2 · 95% CI -12.4 to -8.0
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.6 · 95% CI -12.7 to -8.4
SecondaryPercent Change From Baseline in Body Weight in LY3502970 and Placebo

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight in LY3502970 and Placebo
Percent change12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Percent Change From Baseline in Body Weight in LY3502970 and Placebo-9.4 ± 1.05-12.5 ± 1.01-13.5 ± 0.95-14.7 ± 0.94-2.3 ± 1.00
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -7.1 · 95% CI -9.9 to -4.2
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.1 · 95% CI -12.9 to -7.3
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.1 · 95% CI -13.8 to -8.4
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -12.3 · 95% CI -15.0 to -9.6
SecondaryChange From Baseline in Body Weight in LY3502970 and Placebo

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight in LY3502970 and Placebo
kg12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Change From Baseline in Body Weight in LY3502970 and Placebo-9.0 ± 0.90-12.3 ± 0.86-12.9 ± 0.82-13.3 ± 0.79-2.1 ± 0.86
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -6.9 · 95% CI -9.3 to -4.4
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.2 · 95% CI -12.5 to -7.8
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.8 · 95% CI -13.1 to -8.5
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.2 · 95% CI -13.5 to -8.9
SecondaryChange From Baseline in Body Weight in LY3502970 and Placebo

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight in LY3502970 and Placebo
kg12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Change From Baseline in Body Weight in LY3502970 and Placebo-9.8 ± 1.10-13.6 ± 1.06-14.2 ± 1.00-15.4 ± 0.98-2.4 ± 1.05
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -7.4 · 95% CI -10.4 to -4.3
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.2 · 95% CI -14.2 to -8.3
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -11.8 · 95% CI -14.7 to -9.0
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -13.0 · 95% CI -15.8 to -10.2
SecondaryChange From Baseline in Waist Circumference in LY3502970 and Placebo

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · centimeter (cm)
Change From Baseline in Waist Circumference in LY3502970 and Placebo
centimeter (cm)12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Change From Baseline in Waist Circumference in LY3502970 and Placebo-8.0 ± 1.03-8.8 ± 1.00-10.1 ± 0.94-12.2 ± 0.93-3.6 ± 0.99
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = 0.002 · Ls mean difference (final values): -4.4 · 95% CI -7.2 to -1.6
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -5.2 · 95% CI -8.0 to -2.4
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -6.5 · 95% CI -9.2 to -3.8
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -8.7 · 95% CI -11.3 to -6.0
SecondaryChange From Baseline in Waist Circumference in LY3502970 and Placebo

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · cm
Change From Baseline in Waist Circumference in LY3502970 and Placebo
cm12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Change From Baseline in Waist Circumference in LY3502970 and Placebo-9.6 ± 1.18-11.2 ± 1.15-10.6 ± 1.06-13.6 ± 1.07-4.0 ± 1.12
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -5.6 · 95% CI -8.8 to -2.4
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -7.2 · 95% CI -10.3 to -4.0
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -6.6 · 95% CI -9.7 to -3.6
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -9.6 · 95% CI -12.7 to -6.6
SecondaryChange From Baseline in BMI in LY3502970 and Placebo

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kilograms per meter square (kg/m^2)
Change From Baseline in BMI in LY3502970 and Placebo
kilograms per meter square (kg/m^2)12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Change From Baseline in BMI in LY3502970 and Placebo-3.2 ± 0.31-4.2 ± 0.30-4.6 ± 0.28-4.7 ± 0.27-0.8 ± 0.29
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -2.4 · 95% CI -3.2 to -1.6
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -3.5 · 95% CI -4.3 to -2.6
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -3.8 · 95% CI -4.6 to 3.0
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -3.9 · 95% CI -4.7 to -3.1
SecondaryChange From Baseline in BMI in LY3502970 and Placebo

LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · kg/m^2
Change From Baseline in BMI in LY3502970 and Placebo
kg/m^212 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Change From Baseline in BMI in LY3502970 and Placebo-3.4 ± 0.38-4.7 ± 0.36-5.0 ± 0.34-5.5 ± 0.34-0.9 ± 0.36
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -2.5 · 95% CI -3.6 to -1.5
  • 24 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -3.8 · 95% CI -4.8 to -2.8
  • 36 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -4.2 · 95% CI -5.2 to -3.2
  • 45 mg LY3502970 vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -4.6 · 95% CI -5.6 to -3.6
SecondaryPercentage of Participants With >=5% Body Weight Loss

Percentage of participants with \>=5% body weight loss was reported.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With >=5% Body Weight Loss
percentage of participants12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Percentage of Participants With >=5% Body Weight Loss74.3988.8489.4687.2622.88
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 9.96 · 95% CI 3.61 to 27.44
  • 24 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 27.97 · 95% CI 8.15 to 96.01
  • 36 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 27.36 · 95% CI 8.71 to 85.91
  • 45 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 23.59 · 95% CI 7.65 to 72.77
SecondaryPercentage of Participants With >=10% Body Weight Loss

Percentage of participants with \>=10% body weight loss was reported.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With >=10% Body Weight Loss
percentage of participants12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Percentage of Participants With >=10% Body Weight Loss39.3956.6171.3069.862.25
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 19.93 · 95% CI 3.47 to 114.40
  • 24 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 39.52 · 95% CI 6.95 to 224.83
  • 36 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 74.97 · 95% CI 13.16 to 427.18
  • 45 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 72.23 · 95% CI 12.62 to 413.21
SecondaryPercentage of Participants With >=5% Body Weight Loss

Percentage of participants with \>=5% body weight loss was reported.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With >=5% Body Weight Loss
percentage of participants12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Percentage of Participants With >=5% Body Weight Loss72.0089.4792.0590.4424.02
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.79 · 95% CI 2.90 to 20.92
  • 24 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 25.07 · 95% CI 7.49 to 83.91
  • 36 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 34.76 · 95% CI 8.17 to 147.86
  • 45 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.01 · 95% CI 8.15 to 96.29
SecondaryPercentage of Participants With >=10% Body Weight Loss

Percentage of participants with \>=10% body weight loss was reported.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With >=10% Body Weight Loss
percentage of participants12 mg LY350297024 mg LY350297036 mg LY350297045 mg LY3502970Placebo
Percentage of Participants With >=10% Body Weight Loss46.5061.8874.7569.078.85
Statistical analysis
  • 12 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.27 · 95% CI 2.59 to 26.45
  • 24 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 15.64 · 95% CI 4.83 to 50.68
  • 36 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 27.24 · 95% CI 8.39 to 88.38
  • 45 mg LY3502970 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 20.88 · 95% CI 6.59 to 66.17

Adverse events

Collected over Baseline through Week 38 (36 weeks with 2 weeks safety follow up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12 mg LY35029700/50 (0%)0/50 (0%)35/50 (70%)
24 mg LY35029700/53 (0%)2/53 (3.8%)46/53 (86.8%)
36 Mg-1 LY35029700/29 (0%)0/29 (0%)23/29 (79.3%)
36 Mg-2 LY35029700/29 (0%)3/29 (10.3%)25/29 (86.2%)
45 Mg-1 LY35029700/31 (0%)2/31 (6.5%)26/31 (83.9%)
45 Mg-2 LY35029700/30 (0%)0/30 (0%)24/30 (80%)
Placebo0/50 (0%)0/50 (0%)27/50 (54%)
Most frequent serious events
Most frequent serious events
Event12 mg LY350297024 mg LY350297036 Mg-1 LY350297036 Mg-2 LY350297045 Mg-1 LY350297045 Mg-2 LY3502970Placebo
Retinal vein thrombosisEye disorders0/500/530/291/290/310/300/50
Diverticulum intestinalGastrointestinal disorders0/500/530/291/290/310/300/50
HypercalcaemiaMetabolism and nutrition disorders0/500/530/291/290/310/300/50
Hepatic cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/500/530/291/290/310/300/50
Coronary artery diseaseCardiac disorders0/500/530/290/291/310/300/50
Vitreoretinal traction syndromeEye disorders0/500/530/290/291/310/300/50
Gastrointestinal polyp haemorrhageGastrointestinal disorders0/501/530/290/290/310/300/50
Cholecystitis acuteHepatobiliary disorders0/501/530/290/290/310/300/50
Most frequent other events
Showing 10 of 36
Most frequent other events
Event12 mg LY350297024 mg LY350297036 Mg-1 LY350297036 Mg-2 LY350297045 Mg-1 LY350297045 Mg-2 LY3502970Placebo
NauseaGastrointestinal disorders25/5031/5312/2914/2913/3111/305/50
DiarrhoeaGastrointestinal disorders12/5019/531/294/295/3110/305/50
ConstipationGastrointestinal disorders12/5017/538/297/296/314/303/50
VomitingGastrointestinal disorders13/5017/538/294/299/318/303/50
Covid-19Infections and infestations9/509/534/297/295/315/309/50
EructationGastrointestinal disorders9/5011/535/292/292/316/300/50
DyspepsiaGastrointestinal disorders8/504/531/291/293/312/303/50
HeadacheNervous system disorders4/508/533/292/294/312/305/50
Gastrooesophageal reflux diseaseGastrointestinal disorders4/505/533/294/294/312/301/50
FatigueGeneral disorders2/507/534/292/294/314/301/50

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)12 mg LY350297024 mg LY350297036 mg -1 LY350297036 mg -2 LY350297045 mg -1 LY350297045 mg -2 LY3502970PlaceboTotal
Mean49.80 ± 10.5157.00 ± 9.0956.30 ± 11.8355.40 ± 10.9356.50 ± 10.7450.90 ± 12.5854.00 ± 8.8254.20 ± 10.67
Sex: Female, Male
Sex: Female, Male(Participants)12 mg LY350297024 mg LY350297036 mg -1 LY350297036 mg -2 LY350297045 mg -1 LY350297045 mg -2 LY3502970PlaceboTotal
Female31301818191629161
Male19231111121421111
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)12 mg LY350297024 mg LY350297036 mg -1 LY350297036 mg -2 LY350297045 mg -1 LY350297045 mg -2 LY3502970PlaceboTotal
Hispanic or Latino1164247539
Not Hispanic or Latino38462326252243223
Unknown or Not Reported112121210
Race (NIH/OMB)
Race (NIH/OMB)(Participants)12 mg LY350297024 mg LY350297036 mg -1 LY350297036 mg -2 LY350297045 mg -1 LY350297045 mg -2 LY3502970PlaceboTotal
American Indian or Alaska Native01000001
Asian00000022
Native Hawaiian or Other Pacific Islander00000000
Black or African American364410119
White47462525293045247
More than one race00000022
Unknown or Not Reported00001001
Region of Enrollment
Region of Enrollment(Participants)12 mg LY350297024 mg LY350297036 mg -1 LY350297036 mg -2 LY350297045 mg -1 LY350297045 mg -2 LY3502970PlaceboTotal
Canada9115395648
Hungary653633531
United States35372120192239193
Baseline Body Weight
Baseline Body Weight(Kilograms (kg))12 mg LY350297024 mg LY350297036 mg -1 LY350297036 mg -2 LY350297045 mg -1 LY350297045 mg -2 LY3502970PlaceboTotal
Mean107.49 ± 25.34112.05 ± 30.18107.78 ± 22.45108.84 ± 28.52105.23 ± 20.40110.85 ± 28.11107.57 ± 25.24108.68 ± 26.03
08

Study locations

35 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • John Muir Physician Network Research Center
    Concord, California 94520, United States
  • NorCal Medical Research, Inc
    Greenbrae, California 94904, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Norcal Endocrinology & Internal Medicine
    San Ramon, California 94583, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
    Pittsburgh, Pennsylvania 15243, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Diabetes and Thyroid Center of Fort Worth
    Fort Worth, Texas 76132, United States
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas 78681, United States
  • National Clinical Research, Inc
    Richmond, Virginia 23294, United States
  • St. Vincent Hospital d/b/a Prevea Health
    Green Bay, Wisconsin 54303, United States
  • C-health Research
    Calgary, Alberta T2V 4J2, Canada
  • Wharton Medical Clinic
    Hamilton, Ontario L8L 5G8, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, Ontario N7T 4X3, Canada
  • Centre Médical et Professionnel de l'Ouest de Portneuf
    Saint Marc des Carrières, Quebec G0A 4B0, Canada
  • Alpha Recherche Clinique
    Quebec, G2J 0C4, Canada
  • ALPHA Recherche Clinique
    Quebec, G3K 2P8, Canada
  • Studium Egeszseghaz Kft
    Kalocsa, Bács-Kiskun 6300, Hungary
  • Bugát Pál Kórház
    Gyongyos, Heves 3200, Hungary
  • DRC Gyógyszervizsgáló Központ
    Balatonfüred, Veszprém 8230, Hungary
  • Kanizsai Dorottya Korhaz
    Nagykanizsa, Zala 8800, Hungary
  • Szent Margit Rendelőintézet Nonprofit Kft
    Budapest, 1032, Hungary
  • Clinexpert Kft.
    Budapest, 1033, Hungary
  • TRANTOR'99 Bt. Anyagcsere Centrum
    Budapest, 1213, Hungary
  • Strazsahegy Medicina Bt.
    Budapest, H1171, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Puerto Rico Medical Research
    Ponce, 00717, Puerto Rico
  • Research and Cardiovascular Corp.
    Ponce, 00717, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2022, 10 months.

Results were first posted in Sep 2023, 1 year after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2021
First posted
Sep 21, 2021
StartActual
Sep 29, 2021
Primary completionActual
Aug 25, 2022
CompletionActual
Nov 22, 2022
Results first posted
Sep 13, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05051579
Responsible party
Sponsor
First posted
Sep 21, 2021
Start date
Sep 29, 2021
Primary completion
Aug 25, 2022
Completion
Nov 22, 2022
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-5615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion